Citation Impact
Citing Papers
Potent CRISPR-Cas9 inhibitors from Staphylococcus genomes
2020 StandoutNobel
Rationally engineered Cas9 nucleases with improved specificity
2015 StandoutScience
Machine learning predicts new anti-CRISPR proteins
2020 StandoutNobel
Four-component protein nanocages designed by programmed symmetry breaking
2024 StandoutNatureNobel
Therapeutic siRNA: state of the art
2020
Lipid nanoparticle technology for therapeutic gene regulation in the liver
2020
Efficient Delivery of Antisense Oligonucleotides Using Bioreducible Lipid Nanoparticles In Vitro and In Vivo
2020
Engineering precision nanoparticles for drug delivery
2020 Standout
A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events
2015
Short-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot study
1999
Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
2015 Standout
High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects
2016 StandoutNature
Reactions in Droplets in Microfluidic Channels
2006 Standout
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Treatment of Pulmonary Arterial Hypertension
2004 Standout
Dexamethasone prodrugs as potent suppressors of the immunostimulatory effects of lipid nanoparticle formulations of nucleic acids
2018
Raynaud's phenomenon
1997
State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers
2008
Systemic sclerosis
2017 Standout
Therapeutic application of small interfering RNA directed against bcr-abl transcripts to a patient with imatinib-resistant chronic myeloid leukaemia
2007
An ionizable lipid toolbox for RNA delivery
2021 StandoutNobel
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles
2010 StandoutNature
Single-Stranded DNA Cleavage by Divergent CRISPR-Cas9 Enzymes
2015 StandoutNobel
Metazoan MicroRNAs
2018 Standout
Non-viral vectors for gene-based therapy
2014 Standout
Pharmacotherapy of Raynaudʼs Phenomenon
1996
In vivo genome editing using Staphylococcus aureus Cas9
2015 StandoutNature
New Therapies for Reducing Low-Density Lipoprotein Cholesterol
2014
Sickle-cell disease
2010 Standout
Conformational control of DNA target cleavage by CRISPR–Cas9
2015 StandoutNatureNobel
Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins
2022
Regulatory Functions of the Vascular Endothelium
1990 StandoutNobel
Functional mapping and annotation of genetic associations with FUMA
2017 Standout
Photoplethysmographic assessment of pulse wave reflection
1999
Applications of CRISPR technologies in research and beyond
2016 StandoutNobel
CRISPR/Cas9 cleavage of viral DNA efficiently suppresses hepatitis B virus
2015 StandoutNobel
A thermostable Cas9 with increased lifetime in human plasma
2017 StandoutNobel
Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial
2010
Biology and Applications of CRISPR Systems: Harnessing Nature’s Toolbox for Genome Engineering
2016 StandoutNobel
The Severe Hypercholesterolemia Phenotype
2014
The Pathogenesis of Coronary Artery Disease and the Acute Coronary Syndromes
1992 Standout
Injectable Microbubbles as Contrast Agents for Diagnostic Ultrasound Imaging: The Key Role of Perfluorochemicals
2003
CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes
2016 Standout
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Translating genome-wide association findings into new therapeutics for psychiatry
2016
Refined sgRNA efficacy prediction improves large- and small-scale CRISPR–Cas9 applications
2017 StandoutNobel
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
2015
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Interspecies scaling and prediction of human clearance: comparison of small- and macro-molecule drugs
2011
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
2015 Standout
Massively parallel kinetic profiling of natural and engineered CRISPR nucleases
2020 StandoutNobel
Delivery and Specificity of CRISPR/Cas9 Genome Editing Technologies for Human Gene Therapy
2015
The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity
2022 StandoutNobel
2016
Ionizable Lipid Nanoparticles for In Vivo mRNA Delivery to the Placenta during Pregnancy
2023 StandoutNobel
Biochemical surrogate markers of hemolysis do not correlate with directly measured erythrocyte survival in sickle cell anemia
2016
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
2006 Standout
Lipidoid Tail Structure Strongly Influences siRNA Delivery Activity
2016
Targeted and Equally Distributed Delivery of mRNA to Organs with Pentaerythritol-Based One-Component Ionizable Amphiphilic Janus Dendrimers
2023 StandoutNobel
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
One-Component Multifunctional Sequence-Defined Ionizable Amphiphilic Janus Dendrimer Delivery Systems for mRNA
2021 StandoutNobel
Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics
2019
Prognostic Impact of Coronary Vasodilator Dysfunction on Adverse Long-Term Outcome of Coronary Heart Disease
2000 Standout
CRISPR-Cas: biology, mechanisms and relevance
2016 StandoutNobel
Single-nanometer iron oxide nanoparticles as tissue-permeable MRI contrast agents
2021 StandoutNobel
RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
2016
First-in-Human Phase I Study of the Liposomal RNA Interference Therapeutic Atu027 in Patients With Advanced Solid Tumors
2014
Lipid Delivery Systems for Nucleic-Acid-Based-Drugs: From Production to Clinical Applications
2019
Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers
2021 StandoutNobel
Mikrobläschen als Kontrastmittel für die diagnostische Ultraschall‐Bildgebung: die Schlüsselrolle von Perfluorverbindungen
2003
Bacterial Topoisomerase Inhibitors: Quinolone and Pyridone Antibacterial Agents
2005
EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma
2018 Standout
Emerging Targets in Photopharmacology
2016 StandoutNobel
Investigational nanomedicines in 2016: a review of nanotherapeutics currently undergoing clinical trials
2016
Scalable mRNA and siRNA Lipid Nanoparticle Production Using a Parallelized Microfluidic Device
2021 StandoutNobel
Optimized contrast‐enhanced ultrasonography for characterization of focal liver lesions in cirrhosis: A single‐center retrospective study
2014
Aortic Pulse-Wave Velocity and Its Relationship to Mortality in Diabetes and Glucose Intolerance
2002 Standout
Rational Design of Bisphosphonate Lipid-like Materials for mRNA Delivery to the Bone Microenvironment
2022 StandoutNobel
CRISPR-Cas guides the future of genetic engineering
2018 StandoutScienceNobel
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines
2019 Standout
Works of Timothy Mant being referenced
Comparison of intravenous infusions of iloprost and oral nifedipine in treatment of Raynaud's phenomenon in patients with systemic sclerosis: a double blind randomised study.
1989
Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
2013
The tolerance and pharmacokinetics of clinafloxacin (CI-960) in healthy subjects
1996
Phase I Trial of ISIS 104838, a 2′-Methoxyethyl Modified Antisense Oligonucleotide Targeting Tumor Necrosis Factor-α
2002
Clinical Safety of SonoVue™, a New Contrast Agent for Ultrasound Imaging, in Healthy Volunteers and in Patients with Chronic Obstructive Pulmonary Disease
2001
A phase 1 study of prasugrel in patients with sickle cell disease: pharmacokinetics and effects on ex vivo platelet reactivity
2012
GBT440, a Potent Anti-Sickling Hemoglobin Modifier Reduces Hemolysis, Improves Anemia and Nearly Eliminates Sickle Cells in Peripheral Blood of Patients with Sickle Cell Disease
2015
Haemodynamic effects of inhibition of nitric oxide synthase and of L-arginine at rest and during exercise
1998